PRTA
Price
$8.67
Change
+$0.36 (+4.33%)
Updated
Sep 24, 12:23 PM (EDT)
Capitalization
447.33M
36 days until earnings call
SVRA
Price
$3.52
Change
+$0.04 (+1.15%)
Updated
Sep 24, 12:30 PM (EDT)
Capitalization
601.47M
43 days until earnings call
Interact to see
Advertisement

PRTA vs SVRA

Header iconPRTA vs SVRA Comparison
Open Charts PRTA vs SVRABanner chart's image
Prothena
Price$8.67
Change+$0.36 (+4.33%)
Volume$200
Capitalization447.33M
Savara
Price$3.52
Change+$0.04 (+1.15%)
Volume$1K
Capitalization601.47M
PRTA vs SVRA Comparison Chart in %
Loading...
PRTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PRTA vs. SVRA commentary
Sep 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PRTA is a Hold and SVRA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 24, 2025
Stock price -- (PRTA: $8.31 vs. SVRA: $3.48)
Brand notoriety: PRTA and SVRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PRTA: 43% vs. SVRA: 54%
Market capitalization -- PRTA: $447.33M vs. SVRA: $601.47M
PRTA [@Biotechnology] is valued at $447.33M. SVRA’s [@Biotechnology] market capitalization is $601.47M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PRTA’s FA Score shows that 0 FA rating(s) are green whileSVRA’s FA Score has 0 green FA rating(s).

  • PRTA’s FA Score: 0 green, 5 red.
  • SVRA’s FA Score: 0 green, 5 red.
According to our system of comparison, SVRA is a better buy in the long-term than PRTA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PRTA’s TA Score shows that 3 TA indicator(s) are bullish while SVRA’s TA Score has 4 bullish TA indicator(s).

  • PRTA’s TA Score: 3 bullish, 4 bearish.
  • SVRA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both PRTA and SVRA are a bad buy in the short-term.

Price Growth

PRTA (@Biotechnology) experienced а +1.84% price change this week, while SVRA (@Biotechnology) price change was -4.13% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.31%. For the same industry, the average monthly price growth was +10.10%, and the average quarterly price growth was +53.89%.

Reported Earning Dates

PRTA is expected to report earnings on Oct 30, 2025.

SVRA is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+4.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SVRA($601M) has a higher market cap than PRTA($447M). SVRA YTD gains are higher at: 13.355 vs. PRTA (-40.000). SVRA has higher annual earnings (EBITDA): -116.49M vs. PRTA (-248.1M). PRTA has more cash in the bank: 371M vs. SVRA (146M). PRTA has less debt than SVRA: PRTA (9.78M) vs SVRA (29.7M). PRTA has higher revenues than SVRA: PRTA (10.3M) vs SVRA (0).
PRTASVRAPRTA / SVRA
Capitalization447M601M74%
EBITDA-248.1M-116.49M213%
Gain YTD-40.00013.355-300%
P/E RatioN/AN/A-
Revenue10.3M0-
Total Cash371M146M254%
Total Debt9.78M29.7M33%
FUNDAMENTALS RATINGS
PRTA vs SVRA: Fundamental Ratings
PRTA
SVRA
OUTLOOK RATING
1..100
6280
VALUATION
overvalued / fair valued / undervalued
1..100
55
Fair valued
68
Overvalued
PROFIT vs RISK RATING
1..100
10063
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
6342
P/E GROWTH RATING
1..100
94100
SEASONALITY SCORE
1..100
5090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRTA's Valuation (55) in the Biotechnology industry is in the same range as SVRA (68). This means that PRTA’s stock grew similarly to SVRA’s over the last 12 months.

SVRA's Profit vs Risk Rating (63) in the Biotechnology industry is somewhat better than the same rating for PRTA (100). This means that SVRA’s stock grew somewhat faster than PRTA’s over the last 12 months.

PRTA's SMR Rating (98) in the Biotechnology industry is in the same range as SVRA (99). This means that PRTA’s stock grew similarly to SVRA’s over the last 12 months.

SVRA's Price Growth Rating (42) in the Biotechnology industry is in the same range as PRTA (63). This means that SVRA’s stock grew similarly to PRTA’s over the last 12 months.

PRTA's P/E Growth Rating (94) in the Biotechnology industry is in the same range as SVRA (100). This means that PRTA’s stock grew similarly to SVRA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PRTASVRA
RSI
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
72%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
64%
Bullish Trend 1 day ago
77%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
78%
MACD
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 9 days ago
82%
Declines
ODDS (%)
Bearish Trend 10 days ago
86%
Bearish Trend 1 day ago
85%
BollingerBands
ODDS (%)
N/A
Bearish Trend 1 day ago
80%
Aroon
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
PRTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WAMFX24.000.01
+0.04%
Boston Trust Walden Midcap
MCRTX66.23N/A
N/A
Morgan Stanley Insight R6
VGRTX83.99-0.04
-0.05%
JPMorgan US Value R2
SPMAX12.32-0.02
-0.16%
Saratoga Mid Capitalization A
FCUIX20.87-0.16
-0.76%
NYLI PineStone U.S. Equity Class I

PRTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRTA has been loosely correlated with RCKT. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if PRTA jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRTA
1D Price
Change %
PRTA100%
+0.24%
RCKT - PRTA
51%
Loosely correlated
-2.52%
SVRA - PRTA
45%
Loosely correlated
-0.29%
DNLI - PRTA
40%
Loosely correlated
-2.03%
NUVB - PRTA
35%
Loosely correlated
-1.53%
OCUL - PRTA
35%
Loosely correlated
+0.41%
More

SVRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, SVRA has been loosely correlated with RCKT. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if SVRA jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SVRA
1D Price
Change %
SVRA100%
-0.29%
RCKT - SVRA
60%
Loosely correlated
-2.52%
PRTA - SVRA
45%
Loosely correlated
+0.24%
OCUL - SVRA
39%
Loosely correlated
+0.41%
IFRX - SVRA
39%
Loosely correlated
-3.70%
SRRK - SVRA
38%
Loosely correlated
+3.59%
More